Nicotinamide protects human beta cells against chemically-induced necrosis, but not against cytokine-induced apoptosis

Nicotinamide intervention trials are presently undertaken to prevent Type I (insulin-dependent) diabetes in high risk subjects. They are based on studies in rodents reporting nicotinamide protection against beta-cell injury in vitro and in vivo. This study examines whether nicotinamide can protect h...

Full description

Saved in:
Bibliographic Details
Published inDiabetologia Vol. 42; no. 1; pp. 55 - 59
Main Authors Hoorens, A., Pipeleers, D.
Format Journal Article
LanguageEnglish
Published Berlin Springer 01.01.1999
Subjects
Online AccessGet full text
ISSN0012-186X
1432-0428
DOI10.1007/s001250051113

Cover

Loading…
Abstract Nicotinamide intervention trials are presently undertaken to prevent Type I (insulin-dependent) diabetes in high risk subjects. They are based on studies in rodents reporting nicotinamide protection against beta-cell injury in vitro and in vivo. This study examines whether nicotinamide can protect human beta cells in vitro. At concentrations (2 and 5 mmol/l) to protect rat beta cells against necrosis by streptozotocin or hydrogen peroxide, nicotinamide prevents hydrogen peroxide-induced necrosis of human beta cells. As with rat beta cells, nicotinamide fails to protect human beta cells against apoptosis induced by a combination of the cytokines interleukin-1beta, interferon-gamma and tumour necrosis factor-alpha. In rat beta cells, nicotinamide (2 to 20 mmol/l) was also found to induce apoptosis, in particular during the days following its protection against necrosis; this cytotoxic effect was not observed with human beta cells. These data demonstrate that nicotinamide can protect human beta cells against radical-induced necrosis, but not against cytokine-induced apoptosis. This effect is not associated with a delayed apoptosis as in rat beta cells.
AbstractList Nicotinamide intervention trials are presently undertaken to prevent Type I (insulin-dependent) diabetes in high risk subjects. They are based on studies in rodents reporting nicotinamide protection against beta-cell injury in vitro and in vivo. This study examines whether nicotinamide can protect human beta cells in vitro. At concentrations (2 and 5 mmol/l) to protect rat beta cells against necrosis by streptozotocin or hydrogen peroxide, nicotinamide prevents hydrogen peroxide-induced necrosis of human beta cells. As with rat beta cells, nicotinamide fails to protect human beta cells against apoptosis induced by a combination of the cytokines interleukin-1beta, interferon-gamma and tumour necrosis factor-alpha. In rat beta cells, nicotinamide (2 to 20 mmol/l) was also found to induce apoptosis, in particular during the days following its protection against necrosis; this cytotoxic effect was not observed with human beta cells. These data demonstrate that nicotinamide can protect human beta cells against radical-induced necrosis, but not against cytokine-induced apoptosis. This effect is not associated with a delayed apoptosis as in rat beta cells.Nicotinamide intervention trials are presently undertaken to prevent Type I (insulin-dependent) diabetes in high risk subjects. They are based on studies in rodents reporting nicotinamide protection against beta-cell injury in vitro and in vivo. This study examines whether nicotinamide can protect human beta cells in vitro. At concentrations (2 and 5 mmol/l) to protect rat beta cells against necrosis by streptozotocin or hydrogen peroxide, nicotinamide prevents hydrogen peroxide-induced necrosis of human beta cells. As with rat beta cells, nicotinamide fails to protect human beta cells against apoptosis induced by a combination of the cytokines interleukin-1beta, interferon-gamma and tumour necrosis factor-alpha. In rat beta cells, nicotinamide (2 to 20 mmol/l) was also found to induce apoptosis, in particular during the days following its protection against necrosis; this cytotoxic effect was not observed with human beta cells. These data demonstrate that nicotinamide can protect human beta cells against radical-induced necrosis, but not against cytokine-induced apoptosis. This effect is not associated with a delayed apoptosis as in rat beta cells.
Nicotinamide intervention trials are presently undertaken to prevent Type I (insulin-dependent) diabetes in high risk subjects. They are based on studies in rodents reporting nicotinamide protection against beta-cell injury in vitro and in vivo. This study examines whether nicotinamide can protect human beta cells in vitro. At concentrations (2 and 5 mmol/l) to protect rat beta cells against necrosis by streptozotocin or hydrogen peroxide, nicotinamide prevents hydrogen peroxide-induced necrosis of human beta cells. As with rat beta cells, nicotinamide fails to protect human beta cells against apoptosis induced by a combination of the cytokines interleukin-1beta, interferon-gamma and tumour necrosis factor-alpha. In rat beta cells, nicotinamide (2 to 20 mmol/l) was also found to induce apoptosis, in particular during the days following its protection against necrosis; this cytotoxic effect was not observed with human beta cells. These data demonstrate that nicotinamide can protect human beta cells against radical-induced necrosis, but not against cytokine-induced apoptosis. This effect is not associated with a delayed apoptosis as in rat beta cells.
Author Hoorens, A.
Pipeleers, D.
Author_xml – sequence: 1
  givenname: A.
  surname: Hoorens
  fullname: Hoorens, A.
– sequence: 2
  givenname: D.
  surname: Pipeleers
  fullname: Pipeleers, D.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1737413$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/10027579$$D View this record in MEDLINE/PubMed
BookMark eNpt0U1P3DAQBmALgWD5OPaKfKh6IjCO4zg5VqgtlRBcQOIWjSdecJvYS-wg7b8nEUtXRZx88DOv9Y4P2a4P3jL2RcC5ANAXEUDkCkAJIeQOW4hC5hkUebXLFvNVJqry4YAdxvgHAKQqyn12ME3mWul6wV5uHIXkPPautXw1hGQpRf409ui5sQk52a6LHB_R-Zg4PdneEXbdOnO-Hcm23FsaQnTxjJsxcR_SFq9T-Ou8_UdxFVZptsdsb4ldtCeb84jd__xxd3mVXd_--n35_TojqXTKNLY52AIMWQNQG2UMkda11KalEkkog6qoS1NJraEUbU2YF3VegSxbWZM8Yt_ecqdmz6ONqeldnBuht2GMTVmrqiiFmuDpBo6mt22zGlyPw7p539QEvm4Axqn_ckBPLm6dlroQcmLyjc07iYNdNuQSJhd8GtB1U94cqZv_vm2ayj5Mbd__zL8Cz7KZgw
CitedBy_id crossref_primary_10_1038_sj_bjp_0704156
crossref_primary_10_1111_j_1600_6143_2006_01452_x
crossref_primary_10_3727_096368910X515872
crossref_primary_10_2310_6650_2001_33721
crossref_primary_10_1039_B202503E
crossref_primary_10_3727_000000004783983602
crossref_primary_10_1016_S1499_2671_07_14011_9
crossref_primary_10_1246_cl_2001_1184
crossref_primary_10_1097_TP_0b013e3181d98af1
crossref_primary_10_1007_s00125_012_2713_z
crossref_primary_10_1016_j_abb_2013_03_011
crossref_primary_10_1124_pr_54_3_375
crossref_primary_10_1097_00007890_200201150_00014
crossref_primary_10_2183_pjab_97_022
crossref_primary_10_1251_bpo113
crossref_primary_10_1080_0891693021000010703
crossref_primary_10_1016_j_ejphar_2006_06_016
crossref_primary_10_2337_diabetes_50_3_551
crossref_primary_10_1053_beem_2001_0152
crossref_primary_10_1210_jc_2015_1216
crossref_primary_10_1016_S0006_2952_01_00847_4
crossref_primary_10_1556_JPC_15_2002_6_3
crossref_primary_10_2337_diabetes_51_2007_S462
crossref_primary_10_1097_MPA_0000000000000645
crossref_primary_10_1021_pr500643h
crossref_primary_10_1155_2013_905175
crossref_primary_10_1177_096368970000900314
crossref_primary_10_1016_j_mce_2010_02_016
crossref_primary_10_2337_diabetes_50_8_1771
crossref_primary_10_1006_jaut_2001_0507
crossref_primary_10_1016_S0140_6736_04_15786_3
crossref_primary_10_2337_diabetes_50_5_909
crossref_primary_10_1002__SICI_1099_0801_200004_14_2_69__AID_BMC922_3_0_CO_2_N
crossref_primary_10_1128_MCB_21_16_5605_5613_2001
crossref_primary_10_1046_j_1365_2265_2001_01398_x
crossref_primary_10_1016_S0014_4827_02_00027_7
crossref_primary_10_1152_ajpendo_00320_2003
crossref_primary_10_1021_bm900420f
crossref_primary_10_2337_diabetes_52_7_1683
crossref_primary_10_1111_j_1753_4887_2004_tb00059_x
crossref_primary_10_1007_s00125_008_0936_9
crossref_primary_10_1016_j_pbb_2011_07_003
crossref_primary_10_3389_fimmu_2021_634797
crossref_primary_10_1080_10915810500434183
ContentType Journal Article
Copyright 1999 INIST-CNRS
Copyright_xml – notice: 1999 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1007/s001250051113
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1432-0428
EndPage 59
ExternalDocumentID 10027579
1737413
10_1007_s001250051113
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-Y2
-~C
.55
.86
.GJ
.VR
06C
06D
0R~
0VY
199
1CY
1N0
1SB
203
29F
29G
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
36B
4.4
406
408
409
40D
40E
53G
5GY
5RE
5VS
67Z
6NX
78A
7X7
88E
8AO
8C1
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AABHQ
AACDK
AAEWM
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AAPKM
AARHV
AARTL
AASML
AATNV
AATVU
AAWCG
AAYIU
AAYQN
AAYTO
AAYXX
AAYZH
ABAKF
ABBBX
ABBRH
ABBXA
ABDBE
ABDZT
ABECU
ABFSG
ABFTV
ABHLI
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABLJU
ABMNI
ABMQK
ABNWP
ABOCM
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABUWZ
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACSTC
ACZOJ
ADBBV
ADHHG
ADHIR
ADHKG
ADIMF
ADJJI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AEZWR
AFBBN
AFDYV
AFDZB
AFFNX
AFHIU
AFJLC
AFKRA
AFLOW
AFWTZ
AFZKB
AGAYW
AGDGC
AGJBK
AGMZJ
AGQEE
AGQMX
AGQPQ
AGRTI
AGVAE
AGWIL
AGWZB
AGYKE
AHBYD
AHIZS
AHKAY
AHMBA
AHPBZ
AHSBF
AHWEU
AHYZX
AIAKS
AIGIU
AILAN
AITGF
AIXLP
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
ATHPR
AVWKF
AXYYD
AYFIA
AZFZN
B-.
BA0
BDATZ
BENPR
BGNMA
BPHCQ
BSONS
BVXVI
CAG
CCPQU
CITATION
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
EBLON
EBS
EIOEI
EJD
EN4
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ7
GQ8
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
J5H
JBSCW
JCJTX
JZLTJ
KDC
KOV
KPH
L7B
LAS
LLZTM
M1P
M4Y
MA-
N2Q
N9A
NB0
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P2P
P6G
P9S
PF0
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
PT4
Q2X
QOK
QOR
QOS
R89
R9I
RHV
RIG
ROL
RPX
RRX
RSV
S16
S27
S37
S3B
SAP
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SZ9
SZN
T13
TEORI
TR2
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WH7
WJK
WK8
X7M
YLTOR
Z45
ZGI
ZMTXR
ZOVNA
~EX
~KM
2.D
28-
3O-
5QI
A8Z
AAUYE
ABHQN
ABRTQ
ABWNU
ACUDM
ADKNI
AEFIE
AFEXP
AFOHR
AFQWF
AHAVH
AIIXL
BBWZM
EMB
EMOBN
GRRUI
IQODW
KOW
MVM
NDZJH
PJZUB
PPXIY
R4E
S1Z
S26
S28
SCLPG
SDE
SV3
T16
-53
-5E
-5G
-BR
-EM
3V.
AAAVM
ADINQ
CGR
CUY
CVF
ECM
EIF
GQ6
NPM
Z7U
Z7V
Z7W
Z82
Z83
Z87
Z8O
Z8P
Z8Q
Z8V
Z8W
Z91
Z92
7X8
ID FETCH-LOGICAL-c357t-7ad20e40bceb009b5bbcc77937bdc6ac15ba5496b8377061d9ca24928036d39c3
ISSN 0012-186X
IngestDate Tue Aug 05 10:30:21 EDT 2025
Wed Feb 19 01:20:12 EST 2025
Mon Jul 21 09:14:59 EDT 2025
Tue Jul 01 02:04:38 EDT 2025
Thu Apr 24 23:01:11 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Endocrinopathy
Human
Immunopathology
Cytokine
Langerhans islet
Autoimmune disease
B-Vitamins
In vitro
Necrosis
B-Cell
Cell death
Insulin dependent diabetes
Nicotinamide
Protection
Endocrine pancreas
Apoptosis
Language English
License http://www.springer.com/tdm
CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c357t-7ad20e40bceb009b5bbcc77937bdc6ac15ba5496b8377061d9ca24928036d39c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://link.springer.com/content/pdf/10.1007/s001250051113.pdf
PMID 10027579
PQID 69584615
PQPubID 23479
PageCount 5
ParticipantIDs proquest_miscellaneous_69584615
pubmed_primary_10027579
pascalfrancis_primary_1737413
crossref_citationtrail_10_1007_s001250051113
crossref_primary_10_1007_s001250051113
ProviderPackageCode CITATION
AAYXX
PublicationCentury 1900
PublicationDate 1999-01-01
PublicationDateYYYYMMDD 1999-01-01
PublicationDate_xml – month: 01
  year: 1999
  text: 1999-01-01
  day: 01
PublicationDecade 1990
PublicationPlace Berlin
PublicationPlace_xml – name: Berlin
– name: Germany
PublicationTitle Diabetologia
PublicationTitleAlternate Diabetologia
PublicationYear 1999
Publisher Springer
Publisher_xml – name: Springer
SSID ssj0003546
Score 1.8754497
Snippet Nicotinamide intervention trials are presently undertaken to prevent Type I (insulin-dependent) diabetes in high risk subjects. They are based on studies in...
SourceID proquest
pubmed
pascalfrancis
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 55
SubjectTerms Animals
Apoptosis - drug effects
Apoptosis - physiology
Biological and medical sciences
Cell Survival - drug effects
Cells, Cultured
Cytokines - pharmacology
Diabetes. Impaired glucose tolerance
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Humans
Hydrogen Peroxide - pharmacology
Interferon-gamma - pharmacology
Interleukin-1 - pharmacology
Islets of Langerhans - cytology
Islets of Langerhans - drug effects
Islets of Langerhans - pathology
Male
Medical sciences
Necrosis
Niacinamide - pharmacology
Rats
Rats, Wistar
Recombinant Proteins - pharmacology
Streptozocin - toxicity
Tumor Necrosis Factor-alpha - pharmacology
Title Nicotinamide protects human beta cells against chemically-induced necrosis, but not against cytokine-induced apoptosis
URI https://www.ncbi.nlm.nih.gov/pubmed/10027579
https://www.proquest.com/docview/69584615
Volume 42
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgkxASQtwpsOEHxEsXlMROEz_CFFQQ66puk_pW2Y4zIaa0Ii7S-PUcX3Jpy8TlxYrSo6TK9-X4HMfnOwi9ITxSaSx5wMJMBVTCwCglQVkSyiRMSEKaQuGTyWh8QT_Pk3nX7shWl2jxTv78bV3J_6AK5wBXUyX7D8i2F4UTcAz4wggIw_hXGBsY9VfTUr4w9U5WcaH2bfeE0nxoluXrIb-E9L_WQ-nFAa6uA8jE1_bLvzLTpNMZEGs9rJa6M7_Wy28QhLbGfLVcaWPdj2jdlhrrQlsPPz49neWTs42l0umnaf4lz2dn3Tbjwlffsa3Fhmaxse9RoziIMtuNsPWoNN5hjnOPTpHXT7ROCXzHhbtdG6YjGkRn4DIiV6u6KZW9NYW1GwujlECIRG6j_RjSBtPRIp23CXhIfOFW85-95qotpezfbyNGubfiNUBTuj4nNyciNiA5f4Du-0wCv3e0eIhuqeoRunPi90o8Rj_67MANO7BlBzbswJYd2MONd9mBG3YcYeAGBm50xlvcwC03nqCLj_n58TjwXTYCSZJUBykv4lDREF5KcMFMJEJImRrZRFHIEZdRInhC2UhkJE0h-iuY5EZmMoPYpyBMkqdor1pW6jnCCSuVLJOIlKWioqRZFErC4Cgk8EPGB-ioea4L6SXoTSeUq0Urnt2HYYDetuYrp71yk-HBBkidtaPDAL1uQFuA9zRPl1dqua4XI2YC8CgZoGcOy96NzAf9lL34w7Vforvdi_IK7enva3UAcaoWh5Z8MGbH0SHa_5BPprNfdeeZEg
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nicotinamide+protects+human+beta+cells+against+chemically-induced+necrosis%2C+but+not+against+cytokine-induced+apoptosis&rft.jtitle=Diabetologia&rft.au=HOORENS%2C+A&rft.au=PIPELEERS%2C+D&rft.date=1999-01-01&rft.pub=Springer&rft.issn=0012-186X&rft.volume=42&rft.issue=1&rft.spage=55&rft.epage=59&rft_id=info:doi/10.1007%2Fs001250051113&rft.externalDBID=n%2Fa&rft.externalDocID=1737413
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-186X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-186X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-186X&client=summon